Technetium (99mTc) votumumab
Jump to navigation Jump to search
|Target||tumor antigen CTAA16.88|
|(what is this?)|
Technetium (99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m. It was developed for the detection of colorectal tumors, but has never been marketed.
- "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (1). 1999.
- Hendriks BS, Gaddy DF (2017). "Radiolabeled Antibody-Based Imaging in Clinical Oncology". In Olivier Jr KJ, Hurvitz SA (eds.). Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. Hoboken, New Jersey: John Wiley & Sons. p. 441. ISBN 978-1-119-06084-0.
- "Public Statement on HumaSPECT" (PDF). European Medicines Agency (EMA_. 23 February 2004. Archived from the original (PDF) on 2007-06-10.
Non-renewal of the marketing authorisation in the European Union
- "Summary of Product Characteristics for HumaSPECT" (PDF). European Medicines Agency (EMA).